MetaCap

BioCryst Pharmaceuticals Inc. (BCRX)

NASDAQ: BCRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

7.22-0.10 (-1.37%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BCRX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.28
52-week range
6.23 – 11.22
Day range
7.15 – 7.39
Volume / Avg
3.85M / 4.97M
Beta
—

52-week range

$6.23$11.22

BCRX stock today

On Nov 20, BCRX ended the session at $7.22, shedding $0.10 (1.37%), versus the S&P 500's 3.70% decline. Shares are 35.7% below their 52-week high of $11.22, set on Jul 9, 2026 and 15.9% above the 52-week low of $6.23, near the bottom of the past year's range. BCRX is down 7.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 3.6%.

BioCryst Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.28), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About BioCryst Pharmaceuticals

Company profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Charles K. Gayer
Headquarters
Durham, NC
Employees
435
IPO year
1994

Financial highlights

Full financials

In fiscal 2025, BioCryst Pharmaceuticals generated $874.8 million in revenue, up 94.1% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $263.9 million, for a net margin of 30.2% versus a median of -91.2% in the prior 5 years. Gross margin was 97.8% (up from 97.3%) and operating margin 39.0%.

BioCryst Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$874.84M$450.71M$331.41M$270.83M$157.17M
Growth+94.10%+36.00%+22.37%+72.31%+782.38%
Net income$263.86M$-88.88M$-226.54M$-247.12M$-184.06M
EPS (diluted)$1.21$-0.43$-1.18$-1.33$-1.03

Analyst forecast

Forecast

Consensus (11 analysts)

buy

Avg. price target

$20.45+183.24%

  • Strong buy 2
  • Buy 7
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $11.00High $32.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$0.06 vs $0.10
Surprise
-40.00%

BCRX news

All BCRX news

BioCryst Pharmaceuticals peers

Health Care sector
BCRX peer companies
CompanyPrice% ChgMarket capCompare
COAGHemab Therapeutics Holdings Inc.39.29-1.43%$1.84Bvs BCRX
REPLReplimune Group Inc.19.07-0.83%$1.81Bvs BCRX
LYCALycia Therapeutics Inc.33.07+4.09%$1.72Bvs BCRX
MAZEMaze Therapeutics Inc.31.37-3.27%$1.72Bvs BCRX
BEAMBeam Therapeutics Inc.20.90-0.19%$2.16Bvs BCRX
VIRVir Biotechnology Inc.8.39-5.41%$1.56Bvs BCRX
RXRXRecursion Pharmaceuticals Inc. Class A2.45-9.93%$1.53Bvs BCRX
ALVOAlvotech4.12-3.96%$1.47Bvs BCRX

Indexes, lists and sector

BioCryst Pharmaceuticals stock FAQ

What is BioCryst Pharmaceuticals's stock price today?

BCRX last traded at $7.22 as of Nov 20, 4:00 PM EST, down 1.37% on the day. Prices are delayed at least 15 minutes.

Who is BioCryst Pharmaceuticals's CEO?

Mr. Charles K. Gayer is the chief executive officer of BioCryst Pharmaceuticals Inc., which has about 435 employees.

What is the BCRX 52-week high?

The 52-week high for BCRX is $11.22 and the 52-week low is $6.23. The stock is currently 35.7% below its high.

Compare BCRX